Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Allogene Therapeutics, Inc.

< Previous 1 2 Next >
Allogene Therapeutics Announces Participation in December Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in November Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in September Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Appoints Earl Douglas as General Counsel
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Departure of Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.